Loading clinical trials...

COMPLETEDPHASE3

Complicated Skin and Skin Structure Infections

A Multicenter, Randomized, Double Blind, Comparative Trial of Intravenous MERREM (Meropenem, ICI 194,660) vs PRIMAXIN I.V. (Imipenem-cilastatin) in the Treatment of Hospitalised Subjects With Complicated Skin and Skin Structure Infections.

NCT00619710•Pfizer

View on ClinicalTrials.gov

Summary

The purpose of this study is to demonstrate the non-inferiority of meropenem (Merrem) and imipenem in hospitalised subjects with complicated skin and skin structure infections.

Eligibility

Age

13 - No limit years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•Subjects are hospitalized males and females, aged 13 years or older, with clinical evidence of complicated skin and skin structure bacterial infection with material suitable for culture from 1 primary site of infections
•Within 72 hours before enrollment or at the time of enrollment, all subjects must provide an appropriate specimen for culture and susceptibility testing
•Subjects who have been given prior antibacterial therapy within 14 days of trial entry may be entered only if a culture is obtained showing persistence of a pathogen in blood or at the site of infection

Exclusion Criteria

•Subjects with a known or suspected hypersensitivity to cephalosporins, penicillins, or carbapenems
•Subjects with a history of seizure disorders or subjects currently receiving antiepileptic medication
•Subjects with underlying infections or conditions which would interfere with evaluation of this study

Key Dates

Start Date

February 1, 2001

Primary Completion Date

December 1, 2003

Completion Date

April 1, 2004

Last Updated

September 1, 2017

Enrollment

1,000

ESTIMATED participants

Conditions

Skin InfectionAbscessCellulitis

Interventions

Meropenem

DRUG

Imipenem-cilastatin

DRUG

Clearance of Intracranial Blood Products by Continuous Irrigation With the IRRAflow System

NCT06649097

Intracranial HemorrhageVentriculitis+1 more

View study

RECRUITINGPHASE4

Adjunctive Clindamycin for the Treatment of Skin and Soft Tissue Infections, a Randomized Controlled Trial

NCT05899140

Skin InfectionStaphylococcal Infections+1 more

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: September 1, 2017Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Complicated Skin and Skin Structure Infections

Inclusion Criteria

Exclusion Criteria

Clearance of Intracranial Blood Products by Continuous Irrigation With the IRRAflow System

Adjunctive Clindamycin for the Treatment of Skin and Soft Tissue Infections, a Randomized Controlled Trial

Comparison of Efficacy in Treating Breast Abscess, With Systemic Antibiotics Against Local Instillation of Antibiotics Along With Ultrasound Guided Aspiration.

Multicenter Study for Diagnosis and Treatment of Perianal Abscesses

Bacteriophage Therapy for Mycobacterium Abscessus Pulmonary Infection

Burden of Recreational Water Illness Due to Exposure to Cyanobacteria and Their Toxins in Freshwater Beaches in Canada